Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

被引：0
|
作者：
Yincharoen, P. [1 ]
Samarnthai, N. [2 ]
Korphaisarn, K. [3 ]
Imruetaicharoenchoke, W. [1 ]
机构：
[1] Mahidol Univ, Fac Med, Div Head Neck & Breast Surg, Dept Surg,Siriraj Hosp, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pathol, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Siriraj Hosp, Div Med Oncol, Dept Med,Fac Med, Bangkok, Thailand
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P112
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [22] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 63 - 68
  • [23] Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 63 - 68
  • [24] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [25] Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high risk HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua, Mark Jesus Mendoza
    Swigart, Lamorna Brown
    Renner, Derrick
    Shchegrova, Svetlana
    Hirst, Gillian L.
    Yau, Christina
    Wolf, Denise M.
    Wu, Hsin-Ta
    Kalashnikova, Ekaterina
    Delson, Amy L.
    Chien, A. Jo
    Tripathy, Debu
    Asare, Smita
    Salari, Raheleh
    Rodriguez, Angel
    Zimmermann, Bernhard
    Sethi, Himanshu
    Aleshin, Alexey
    Billings, Paul
    Nanda, Rita
    Rugo, Hope S.
    Esserman, Laura J.
    Liu, Minetta C.
    DeMichele, Angela
    van't Veer, Laura
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Loo, Claudette E.
    Rigter, Lisanne S.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Rodenhuis, Sjoerd
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Sikorska, Karolina
    Gilhuijs, Kenneth G. A.
    BREAST CANCER RESEARCH, 2016, 18
  • [27] Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
    Claudette E. Loo
    Lisanne S. Rigter
    Kenneth E. Pengel
    Jelle Wesseling
    Sjoerd Rodenhuis
    Marie-Jeanne T. F. D. Vrancken Peeters
    Karolina Sikorska
    Kenneth G. A. Gilhuijs
    Breast Cancer Research, 18
  • [28] Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer
    Jung, Youn Joo
    Lee, Seungju
    Kang, Seok Kyeong
    Kim, Jee Yeon
    Choo, Ki Seok
    Nam, Kyung Jin
    Joo, Ji Hyeon
    Kim, Jae Joon
    Kim, Hyun Yul
    ONCOLOGY, 2024,
  • [29] Validation of Magee equation in predicting response to neoadjuvant chemotherapy in breast cancer patients with hormone receptor positive and HER2 negative
    Saigosoom, N.
    O-charoenrat, P.
    Udompunturak, S.
    Sanguanraksa, D.
    BREAST, 2019, 44 : S73 - S73
  • [30] Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 999 - 999
12345